Downloading...
Download

Monkeypox

What news is needed to push the #DXY down? Let's take a look;Do you remember the pandemic period? The markets seemed to crash first, many of us even said, let's keep our money, neither stock market nor investment, let's see the way ahead first, let's not be exposed. Today, they had another case that shook the world. I say they did because I think there is nothing unconsciously done. Does the Monkeypox case look familiar? Could Bitcoin be pricing it in again right now? Not yet; I think today's drop is due to the NYSE withdrawing its offer to trade options on #Bitcoin ETFs. However, they will deepen the situation and it will create a domino effect. For exchanges that shape the world economy and politics, every movement on the charts is very valuable. Although the crypto exchange is not yet at this level, we are sure that it will be much more valuable in the near future. This chart I am sharing with you is the #DXY 1W chart ; It takes big events to make big moves on key charts like this one. It is highly likely to make a pattern like the one in the chart (no one knows tomorrow and the next move 100%). We are traders and our job is to make predictions. In order to make accurate predictions, we have to include all the data that concerns us. And those who make the right predictions and take the right risks always win.
TVC:DXYShort
by ugurtash
Are we looking at the next 20-30% drop in the stock market? First of all, this is not to cause alarm but to look at the JPY chart from a holistic long term view. The last time we posted about a market drop, it came true. This chart is a summary of how we called the DJIA to fall from 35,200 to 29,000. This was also followed up with a posting on the SPX from 4200 to 3700. Looking at the long term view of all the YEN pair, we are seeing massive reversal signs on weekly chart. When YEN strengthens, the stock market falls as risk off sentiment comes back. This will be analyzed looking at the AUDJPY. The pair just completed a Head and Shoulders and it is poised delicately. If it can go above 97 and close strong, we will see the markets go up and the pattern is over. However what is more likely to happen is that the AUDJPY will start dropping down due to the shoulders at 95.80 and head at 97. The first level is 90.32 and then to 87.20. The drop in the AUDJPY is going to be corresponding to the drop in the indexes. How long will this take? I believe it will be a slow grind down. This level is likely to be reached in about October to December timeframe. Would love to hear your thoughts and comments. Cheers
Education
by JavonDias_Trading
Plan for potential "ape" spreadJust a small idea. I like this company; been trading it since 2018 and the pandemic. "In case" the Monkeypox virus spreads, this could be a decent hedge. We saw $SIGA with huge gaps last week (similar play), which likely will open higher on Monday. According to one source; It's spread through droplets and/or contact with infected lesions; skin contact coughs, etc. In other words, this is nothing you only inhale, like Covid" By that, hospital staff would need to wear full protective gear (In worst-case scenario). Alpha Pro Tech makes "high-value disposable Personal Protective Apparel and masks", and I, therefore, expect it to extend its weekly base building and breakout. Entered Thursday. Had a nice PocketPivot and wedge BO from Friday. Stop: 5% start. When 5% gained -> moved to B/E before trailing 5%/ma10. Not my classic setup, but there are not any good breakouts in this market anyway :) Good luck next week.
AMEX:APTLong
by TechFille006
MEDIUM TERM OUTLOOK ON THE DOLLARFor the longest time, I have been debating whether or not to begin posting my trading sentiments since the trading community I look after & am a part of is a very private one. That said. we are in unprecedented times, a lot of people do not know what is coming their way. nevermind how to protect themselves/ take advantage of relevant opportunities. So I have decided to help those who are looking to understand financial markets not only from a trading perspective but from an actual investing perspective. So as my first post, let's take a look at a currency that impacts the rest of the global & emerging market currencies & that can help you plan your trading approach over the next 3 - 6 months. But before we do that kindly understand the following: As a former investment bank trading analyst. There is absolutely noway you can incorporate technical analysis without fundamental analysis. When I see retail traders/people just speak about technical analysis and understand nothing about fundamental dynamics & how it affects trading pairs/executions/decisions as a whole, not only do I laugh but it also makes me understand why there is truly only 5-10% of retail traders globally that are consistently profitable. But enough about that, let's get to the charts! DOLLAR INDEX OUTLOOK: Fundamental ( DOWNSIDE ): If another rate hike takes place & MONKEYPOX cases cross the 10K margin in the US &/or employment numbers (NFP) drop. Technical ( DOWNSIDE ): Should the above fundamental case happen, trading opportunities can be taken advantage of through the WXY scenario, where X represents the entry-point. Fundamental ( UPSIDE ): A rate hike & more stimulus money will see the dollar go up. Mid-term elections being favourable would also send the dollar much higher. Technical (UPSIDE ): The above fundamentals taking place would allow scenario ABC to take effect with point B representing the optimal entry-point for relevant trades. Let us see how it plays out, as for exact entry points and iterations to this post as time goes on, that will be given to members only. However, that said, I am willing to do analysis on different pairs/derivatives' on behalf of those who would appreciate an informed opinion on both the technical and fundamental sides. At the end of the day I want to see traders progressing and doing much better but the truth is you need to understand the markets from a technical & fundamental perspective in order to truly be successful as a trader & ultimately become an active investor in financial markets. If all you have been doing at this point in time is trading only incorporating technical analysis then all you are/have been doing is donating money to the market, your broker/s and my former employers in the investment banking/hedge fun world. :) Don't forget to like & comment, I look forward to beginning this new journey with all of you!! :)))
INDEX:DXY
by No-NonsenseFX_
NBY effective against Monkeypox ! 20X Upside Analyst Rating!!!NovaBay Pharmaceuticals, Inc. (NBY) owns Avenova, which is EPA listed as an effective disinfectant for monkeypox. On 5/20/2022 Ascendiant Capital Markets brokerage set a price target of $4.00 for NovaBay Pharmaceuticals, Inc. (NBY). The stock is now only 0.20usd. Before the pandemic news, on their last earnings, they mentioned that Avenova Spray unit sales increased 15% with record-high units sold through the OTC channel. NovaBay CEO: "we expect the majority of 2022 topline growth to come in the second half of this year." The stock had only insider buys recently, the average being $0.45. Only 10.976Mil MARKET CAP The falling wedge in the chart is a bullish sign. I think we can expect at least a reversal to the $0.64 resistance. Looking forward to read your opinion about it.
AMEX:NBYLong
by TopgOptions
$BVNRY PTs 300-400 and higher Bavarian Nordic is the only company with an FDA approved Monkey Pox Vaccine Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
OTC:BVNRYLong
by BADQOMOCAWGOWLD
1
Pharma firm SIGA cashes in on monkeypox scareNew York-based pharmaceutical firm SIGA Technologies (NASDAQ:SIGA) is among the companies to benefit from the growing threat of monkeypox, recently pushing its shares to an almost decade-high after the company obtained approval in Europe to use its TPOXX antiviral drug for the treatment of monkeypox. Smallpox jabs vs monkeypox On May 19, the World Health Organization declared that vaccines used against smallpox — before the virus was eradicated in 1980 — can be used to fight monkeypox. SIGA already won approval from the US Food and Drug Administration in 2018 to distribute its oral TPOXX capsules as a treatment against smallpox even when there were no reports of confirmed or possible cases of smallpox at the time. US advances in vaccine orders Most recently, SIGA on Thursday secured another approval from the FDA for the intravenous (IV) formulation of TPOXX for patients who are unable to swallow the drug’s oral variant. SIGA said the IV formulation of TPOXX has already been cited in the recent US president’s budget request to treat a patient with monkeypox in the US. The company's shares surged 43% on Friday before paring gains to close 13% lower on the Nasdaq on Monday, and another 15.5% on Tuesday. SIGA stock remains up 26.5% over the past 5 days of trading. SIGA also stands to benefit from TPOXX’s use in Canada and Europe, where cases of moneypox were detected in recent weeks. Europe has already approved the use of TPOXX against monkeypox, cowpox, and complications from immunization with vaccinia, the company said. Growing monkeypox threat Monkeypox, first discovered in 1958, is a viral illness that first occurred in colonies of monkeys. The first human case of the virus was recorded in the Democratic Republic of Congo in 1970, according to the US Centers for Disease Control and Prevention. The virus can cause symptoms like fever, body aches, swollen lymph nodes and bumpy rashes. Cases of monkeypox have so far been reported in at least 17 countries including the US, Canada, the UK, Spain, Portugal, France, Italy and Australia. Big pharma steps in SIGA and another vaccine maker in Denmark, Bavarian Nordic (CPH:BAVA), have kept samples of smallpox virus for research purposes in case of biological warfare. The emergence of monkeypox this year prompted both companies to start mass producing vaccines against smallpox to offer protection against monkeypox. CDC officials on Monday said the US is in the process of releasing Bavarian Nordic’s Jynneos vaccine doses to fight against monkeypox. The US has stockpiled more than 1,000 doses of the vaccine and CDC officials expect to boost their purchases in the coming weeks. Bavarian Nordic’s shares on the Nasdaq Copenhagen surged to a four-month high on Monday. The Danish company on May 18 said the US government has already placed a $119 million order for the production of freeze-dried Jynneos vaccines, although deliveries are not expected until 2023 and 2024. Meanwhile, Moderna (NASDAQ:MRNA), which succeeded in developing vaccines against COVID-19, also started testing vaccines against monkeypox. The company on Tuesday said it is investigating potential vaccines against monkeypox in pre-clinical trials. No urgent need for mass vaccinations Although vaccines against monkeypox are already within reach just weeks into reports of an outbreak emerged, some experts and WHO officials say inoculations against monkeypox will not likely involve a mass campaign as the virus, unlike COVID-19, is not as contagious. Vaccinations would likely be focused only on people with close contact with infected individuals. "If a case is reported in the country, a public health SWAT team goes out, finds out who the close contacts are of that first case, and vaccinates just those close contacts, and not the entire city or suburb,” Dr. David Freedman, professor emeritus of infectious diseases at the University of Alabama, was quoted by Time magazine as saying.
NASDAQ:SIGA
by BlackBull_Markets
TNXP Tonix Pharmaceuticals produces the Monkeypox Vaccine ! Tonix is a producer of the TNX-801 vaccine, effective against Smallpox and Monkeypox. But that`s not all! They have a strong balance sheet, Cash and Cash Equivalents Totaled Approximately $140 Million VS its mk cap of only $44.03Mil. Seth Lederman, M.D., Chief Executive Officer of Tonix: “Tonix is making meaningful strides developing our rich portfolio of high impact product candidates,” “By the end of this year, we expect to have five central nervous system (CNS) programs in the clinic, led by our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development. Enrollment has begun for TNX-102 SL in a registration-enabling-Phase 3 clinical trial. TNX-102 SL trials in Long COVID and PTSD are also expected to initiate enrollment in the second quarter of 2022.” TNX-2900 received Orphan-Drug designation by the FDA for the treatment of PWS in March 2022. On this strong pipeline, on 4/18/2022 Noble Financial Initiated Coverage on TNXP with an Outperform rating and a price target of $19.20, while Alliance Global Partners has a price target of $64. I expect TNXP Tonix Pharmaceuticals to be at least $10 per share. Looking forward to read your opinion about it.
NASDAQ:TNXPLong
by TopgOptions
2
Pox Vaccine/Treatment Long, Dark WinterWith the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of vaccine stocks in the future. Although smallpox is considered eradicated since 1980, considering other variants of smallpox like monkeypox are still present in this world and the lack of immunity among the young (people under the age of 35) from the closure of smallpox vaccine production (we're talking about a ~ 15% fatality rate that goes up to ~40% the younger a person is ), it is still a clear and present danger to society. Doesn't help that the FDA has been more active in approving multiple vaccines and treatments over the last 3 years. . Though the good news is that the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) will target to stockpile enough vaccines for every American according to a 2016 report . PREVENTION As of my knowledge, the following stocks hold a trademark of a vaccine against smallpox: - $EBS, ACAM2000 ® - $BVNRY, holds a trademark of a vaccine against monkeypox, named JYNNEOS® under the FDA . For tradenames of this vaccine under other regions, see the investor news page published this july .Note the JYNNEOS vaccine is the only currently FDA-approved vaccine for the prevention of monkeypox disease and smallpox. These vaccines are not readily available to public, but several treatments are ... more on that below. - $SNY, the Aventis Pasteur Smallpox Vaccine (APSV), that is available in the event that ACAM2000® is depleted within the U.S. Strategic National Stockpile (SNS) which apparently holds 90M doses . Note Aventis was merged with Sanofi in 2004, just to clear up any confusion on any old web pages from before 2004. More details about these vaccines can be found here: www.cdc.gov www.cdc.gov www.fda.gov You could argue $NVAX to be a good pick but I would consider it a long-term play. TREATMENTS The following stocks hold a trademarked treatment against smallpox: - $SIGA , TPOXX® , also known as tecovirimat and ST-246® - $CMRX , Tembexa (brincidofovir) There are many more companies working on treatments/detections against smallpox, so feel free to research and find them before they go public. This idea is merely an inspiration for you to look for and capitalize on this opportunity if it presents itself in the future. Take BioFire as an example, a private company contracted by the DoD to supply them test kits on various biological warfare agents including smallpox . ( Pg 105 of 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Strategy and Implementation Plan). But although there private, they've merged w/ bioMerieux , a publicly-traded company, in January 2014. In the event that the supply of vaccines does meet demand, this could be an alternative strategy seeing as test detection kits may not be in demand at the moment. Especially considering that the awarded NGDS contract was valued at $240M for a period of 8 years, or $30M per year(which corresponds very closely with how much $ was allocated toward JOINT BIOLOGICAL AGENT DECONTAMINATION SYSTEM (JBADS) according to the UNCLASSIFIED Department of Defense Fiscal Year (FY) 2022 Budget Estimates document released in May this year on Page 2 of 91, P-1 line #80 titled CB Protection & Hazard Mitigation, or just page 142 of 754 of the pdf doc). With each kit costing $8K-$9k each for 30 tests , at max the DoD should hold ~30K kits assuming these kits have not been used and have an extended shelf life beyond the lifetime of the awarded gov. contract, and that this budget does not include any other products from BioFire related to the NGDS. 30K units with 30 tests each means 900,000 total possible tests... if they're single-use, it may not be even enough for essential personnel contracted by the gov. Even if you consider smallpox's eradication... it is not reasonable for the gov to spend a bit more on these kits seeing they cover detection on outbreaks outside of smallpox like anthrax, ebola, etc. Thankfully Bill Gates did warn us of bioterror attacks concerning smallpox earlier this year. The same goes for U.S. Government agencies and institutions' wargaming of such an event back in 2001, naming the exercise, Dark Winter . A couple of interesting conclusions from this exercise: -No surge capacity in U.S. healthcare and public health systems. Given how COVID-19 went, not too surprising but as expected -Information management w/ media be crucial for crisis control. Lol, w/ the amount of distrust in the media and gov. this will be sh*tshow. Don't be surprised by draconian levels of control over the flow of info if this outbreak happens. -Renewed vaccine production is estimated to require at least 24-36 months. Big yikes. If a smallpox breakout does happen and vaccine hesitancy continues w/ smallpox vaccines, let alone the supply of these products not being able to catch up to their demand, expect a high amount of casualties and stocks related to the treatment rather than the prevention of smallpox to rise. Nonetheless, the living will be capable of seeing a new and brighter world of the 4th industrial revolution by 2030. Feel free to comment below on any constructive criticism against this idea. I'd like to strengthen it and improve on the quality of future ideas. If my grammar is bad, it is no excuse, but I was raised with poor primary education, it will get better with time. If you agree with this idea, feel free to leave a like and share, thank you.
NASDAQ:SIGALong
by linebands